Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$41.99 USD
-0.53 (-1.25%)
Updated May 10, 2024 04:00 PM ET
After-Market: $42.00 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 41 - 60 ( 276 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre 3Q23 Beat Pre-Announced, But Where Does Retinal Vasculitis Rate Go?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
J-Code Another Catalyst for Syfovre Growth to Resume; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Looks Unscathed by Izervay 24-Month Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Top Nuggets from HC Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Details Boost Our Confidence in Syfovre''s Safety Profile; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Well, If It''s Not The Syringes... Syfovre Retinal Vasculitis Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Signs of Stability Should Get Syfovre Moving Again
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Izervay (Zimura) Enters The Fray A Bit Earlier Than Anticipated
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Plot Thickens in GA Market with Izervay Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Stregnth in 2Q Overshadowed by Safety Concerns as ASRS Stays in Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Live From ASRS Day 2: On the Ground Feedback on Syfovre
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Almost Wish It Was Manufacturing; How Long Will Syfovre Safety Remain In Focus?
Provider: Wedbush Securities Inc.
Analyst: CHICO L